Enhanced 3-Hydroxy-3-methyl-Glutaryl Coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 451-454

  Caruso, Maria Gabriella ^a   Notarnicola, Maria ^a   Santillo, Mariarosaria ^b   Cavallini, Aldo ^a   Di Leo, Alfredo ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b NONE

Author keywords

Colorectal carcinoma; HMG CoA reductase; Low density lipoprotein receptor

Indexed keywords

CARBON 14; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RADIOASSAY; SYNTHESIS;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; MIDDLE AGED; RECEPTORS, LDL;

EID: 0032897822     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Siperstein MD: Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lip Res 25: 1462-1468, 1984.
2. Goldstein JL and Brown MS: The Low Density Lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 46: 897-930, 1977.
3. Betteridge DJ, Krone W, Ford JM and Morris HP: Regulation of sterol synthesis in leukaemic blast cells: a defect resembling familial hypercholesterolaemia. Eur J Clin Invest 9(6): 439-441, 1979.
4. Clayman RV, Bilhartz LE, Buja LM, Spady DK and Dietschy JM: Renal cell carcinoma in the Wistar-Lewis rat: a model for studying the mechanisms of cholesterol acquisition by a tumor in vivo. Cancer Res 46(6): 2958-2963, 1986.
5. Vitols S, Peterson C, Larsson O, Holm P and Aberg B: Elevated uptake of low density lipoproteins by human lung cancer tissue in viro. Cancer Res 52(22): 6244-6247, 1992.
6. Ho YK, Smith RG, Brown MS, and Goldstein JL: Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52(6): 1099-1114, 1978.
7. Vitols S, Gahrton G, Bjorkholm M and Peterson C: Hypocholesterolemia in malignancy due to elevated low density lipoprotein receptor activity in tumor cells: evidence from studies in patients with leukaemia. Lancet 2(8465): 1150-1154, 1985.
8. Vitols S, Gahrton G, Ost A and Peterson C: Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 63(5): 1186-1193, 1984.
9. Rudling MJ, Angelin Bo, Peterson CO and Collins VP: Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res 50: 483-487, 1990.
10. Engstrom W and Schofield PM: Expression of the 3-hydroxy-3-methylglutaryl Coenzyme A reductase and LDL receptor and LDL-receptor penes in Human Embryonic Tumours and in Normal Foetal tissues. Anticancer Research 7(3 Pt B): 337-342, 1987.
11. Maltese WA: 3-Hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurology 33: 1294-1299, 1983.
12. Caruso MG, Notarnicola M, Cavallini A et al: Demonstration of low density lipoprotein receptor in human colonic carcinoma and surrounding mucosa hy immunoenzymatic assay. Ital J Gastroenterol 25: 361-367, 1993.
13. Niendorf A, Nagele H, Gerding D et al: Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer 61: 461-464, 1995.
14. Gebhard RL, Stone BG, Prigge WF: 3-hydroxy-3-methylglutaryl coenzymeA reductase activity in the human gastrointestinal tract. J Lipid Res. 26: 47-53, 1985.
15. Chen HW, Kandutsch AA, Heineger HJ: The role of cholesterol in malignancy. Prog Exp Tumor Res 22: 275-316, 1978.
16. 14 of fatty acids and cholesterol in formed blood elements. Can J Biochem 36: 1125-1136, 1958.
17. Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S, Matsuzawa Y and Tarni S: Increase in the active form of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosyntheis. Cancer Res 50: 3270-3273, 1990.
18. Gebhard RL, Clayman RV, Prigge WF, Figenshan R, Staley NA, Reesay C and Bear A: Abnormal cholesterol metabolism in renal clear cell carcinoma. J Lipid Res 28: 1177-1184, 1987.
19. Caruso MG, Osella AR, Notarnicola M, Berloco P, Leo S, Bonfiglio C, Di Leo A: Prognostic value of Low Density Lipoprotein Receptor expression in colorectal carcinoma. Oncology Reports 5: 927-930, 1998.
20. Broitman SA, Cerda S, Wilkinson J: Cholesterol metabolism and colon cancer. Progress in Food and Nutrition Science 17: 1-40, 1993.
21. Cerda SR, Wilkinson J, Broitman SA: Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines. Lipids 30: 1083-1092, 1995.
22. Brown MS, Goldstein JL and Dietschy JM: Active and inactive forms of 3-Hydroxy-3-methylglutaryl coenzyme A reductase in the liver of the rat. J Biol Chem 254(12): 5144-5149, 1979.
23. Lowry OH, Rosebrough NJ, Farr AL et al: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
24. Harwood HJ Jr, Alvarez IM, Noyes WD, Stacpcole PW: In vivot regulation of human leukocyte 3-hydroxy-3-methylglutaryl Coenzyme A Reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J Lipid Res 32: 1237-1252, 1991.
25. Bos J, Fearon ER, Hamilton SR, Verlaan-de-Vries M, van Boom JH, van der Eb AJ, Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987.
26. Cooper GM and Lane MA. Cellular transforming genes and oncogenesis. Biochim Biophys Acta 738: 9-20, 1984.
27. Schulz S, Klann RC, Schonfeld S, Nyce JW: Mechanisms of Cell Growth Inhibition and Cell Cycle Arrest in human Colonic Adenocarcinoma Cells by Dehydroepiandrosterone: Role of Isoprenoid Biosynthesis. Cancer Res 52: 1372-1376, 1992.
28. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK: Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitor inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Clin Invest 76: 1748-1754, 1985.
29. Sumi SR, Beuchamp RD, Townsend CM, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC: Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103: 982-989, 1992.
30. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J et al: Phase I Study of Lovastatin, an inhibitor of mevalonate pathway in patients with cancer. Clinical Cancer Res 2: 483-491, 1996.